All funds

Cambiar Investors

Mar 2025 → Mar 2026 · Publishes twice a year · 6 funds

Our archive holds 14 letters from Cambiar Investors, behind 9 investment theses and positions in 15 companies. Every quote below is copied verbatim from the letter it came from.

Cambiar Investors’s own letters page
14
Letters
15
Companies
5
Moves
9
Theses

What they bought and sold · 5 moves

Companies held · 15

Every company Cambiar Investors has disclosed a position in across our archive, with the letter that last mentioned it.

Theses · 9

  • ON Semiconductor makes power semiconductors and is seen as a cyclical recovery play with best-in-class management and a datacenter-driven catalyst.

    Read the full thesis
  • Tower Semiconductor is an analog foundry with a strong specialty position and AI optics tailwinds.

    Read the full thesis
  • March 2026

    ACV Auctions is a recession-resistant dealer-to-dealer auto marketplace with strong growth, margins, and recovery upside.

    Read the full thesis
  • Energias de Portugal is an integrated utility with cost-advantaged assets and secular growth tailwinds from datacenters and power demand.

    Read the full thesis
  • September 2025

    ACV Auctions is a dealer-to-dealer car sales platform with recession-proof growth, strong margins, and potential for volume recovery and multiple expansion.

    Read the full thesis
  • September 2025

    Align is the leading clear aligner manufacturer with unmatched scale and strong balance sheet, trading at an attractive valuation with long-term growth intact.

    Read the full thesis
  • September 2025

    Molina Healthcare is a managed Medicaid insurer with rebound potential through higher state reimbursements, conservative earnings recovery assumptions, and substantial insider buying underpinning attractive valuation.

    Read the full thesis
  • September 2025

    Tower Semiconductor is an analog foundry leader in specialty materials and silicon photonics supplying Nvidia, benefiting from high AI datacenter optics demand.

    Read the full thesis
  • Regeneron is a high-quality biopharmaceutical operator with a strong R&D foundation, a robust financial position, and a favorable risk/reward opportunity despite a temporary revenue slowdown for its EYLEA product.

    Read the full thesis

Letter archive · 14

Funds · 6

  • Cambiar International Equity4
  • Cambiar Opportunity Fund3
  • Cambiar Smid Fund3
  • Cambiar Small Cap Fund2
  • Cambiar Smal Cap Fund1
  • Cambiar Smid Cap fund1

Get Cambiar Investors’s next letter the day it lands

We track Cambiar Investors alongside hundreds of other managers, read every letter, and pull out what they bought and sold. Warren AI reads the whole archive for you.

View plans
Share this fund